Role of adipokines and peroxisome proliferator-activated receptors in nonalcoholic fatty liver disease
about
Recent advances in dietary supplementation, in treating non-alcoholic fatty liver disease.Can skin exposure to sunlight prevent liver inflammation?Liver fat deposition and mitochondrial dysfunction in morbid obesity: An approach combining metabolomics with liver imaging and histologyAssociation of Adiponectin gene polymorphisms and nonalcoholic fatty liver disease.Astragaloside IV improves lipid metabolism in obese mice by alleviation of leptin resistance and regulation of thermogenic network.Association of Adiponectin Gene Polymorphisms With the Risk of Coronary Artery Disease in Patients With Nonalcoholic Fatty Liver Disease in a Chinese Han PopulationPPARs and Mitochondrial Metabolism: From NAFLD to HCC.Adipocytokines and hepatic fibrosis.Molecular factors involved in the hypolipidemic- and insulin-sensitizing effects of a ginger (Zingiber officinale Roscoe) extract in rats fed a high-fat diet.Differences and similarities in hepatic lipogenesis, gluconeogenesis and oxidative imbalance in mice fed diets rich in fructose or sucrose.Nanoparticles for the treatment of liver fibrosis.Connexin32 deficiency is associated with liver injury, inflammation and oxidative stress in experimental non-alcoholic steatohepatitis.Palmitate induces fat accumulation by activating C/EBPβ-mediated G0S2 expression in HepG2 cells.Morphofunctional Changes After Sleeve Gastrectomy and Very Low Calorie Diet in an Animal Model of Non-Alcoholic Fatty Liver Disease.Non-Alcoholic Fatty Liver Disease.The effect of minimal dietary changes with raisins in NAFLD patients with non-significant fibrosis: a randomized controlled intervention.The Nuclear Orphan Receptor Nur77 Alleviates Palmitate-induced Fat Accumulation by Down-regulating G0S2 in HepG2 Cells.Future Pharmacotherapy for Non-alcoholic Steatohepatitis (NASH): Review of Phase 2 and 3 Trials
P2860
Q35127037-CDF69872-B4A4-480A-B941-68FEA997C880Q35658038-92754B6B-9C98-4E87-A465-ACFAA90BDC71Q35783949-A01FE604-F92F-4BB0-9F93-A1E904A14CE1Q36318134-B5F47D66-80B6-42D4-BEC5-3FF817873BA4Q37117549-854E3B67-AC09-4A89-9862-C3F1DBB52F8DQ37246571-2E0129B8-FA46-4051-93E7-B7F6418A489AQ37575571-C13FB08D-D148-4719-AA0A-78E147448C89Q38346026-11679EDF-477B-4930-ABD0-8A8908F60922Q38997648-5103F8A4-7856-4FC7-9801-848B7FF8828DQ42172622-78A4A227-4514-4E9C-9CB8-2E7EE43B4431Q42364467-8A77771E-8AB3-4295-BB2A-E39F31745376Q43635935-4B0175F7-8EEE-4C23-B1FC-55131DD4E7E7Q47098862-E8B64320-98DE-40AE-974D-6007F3339A07Q50202622-57EAB817-1130-4E00-9226-98525A6EA2DBQ50957769-EA696FDF-EB82-43A1-AE4E-5F7A5B0F1C2FQ51278231-A4139811-6FE8-4CA6-AE67-90D172EFA05FQ52647847-FA8844BA-9804-410B-A3AE-EF9D65F4E8B5Q57066927-DB28A23E-0D05-4B9E-81A6-194CC7AFD093
P2860
Role of adipokines and peroxisome proliferator-activated receptors in nonalcoholic fatty liver disease
description
2014 nî lūn-bûn
@nan
2014 թուականի Օգոստոսին հրատարակուած գիտական յօդուած
@hyw
2014 թվականի օգոստոսին հրատարակված գիտական հոդված
@hy
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
name
Role of adipokines and peroxis ...... nalcoholic fatty liver disease
@ast
Role of adipokines and peroxis ...... nalcoholic fatty liver disease
@en
Role of adipokines and peroxis ...... nalcoholic fatty liver disease
@nl
type
label
Role of adipokines and peroxis ...... nalcoholic fatty liver disease
@ast
Role of adipokines and peroxis ...... nalcoholic fatty liver disease
@en
Role of adipokines and peroxis ...... nalcoholic fatty liver disease
@nl
prefLabel
Role of adipokines and peroxis ...... nalcoholic fatty liver disease
@ast
Role of adipokines and peroxis ...... nalcoholic fatty liver disease
@en
Role of adipokines and peroxis ...... nalcoholic fatty liver disease
@nl
P2860
P3181
P356
P1476
Role of adipokines and peroxis ...... nalcoholic fatty liver disease
@en
P2093
P2860
P3181
P356
10.4254/WJH.V6.I8.570
P407
P577
2014-08-27T00:00:00Z